Application of Artificial Intelligence & Machine Learning for Precision Medicine
Friday, February 17, 2023
Virtual Event details shared upon registration
The U.S. Food and Drug Administration (FDA) – in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) – will host a one-day virtual public workshop entitled “Application of Artificial Intelligence and Machine Learning for Precision Medicine” on Friday, February 17, 2023.
The purpose of this workshop is to review current methodologies, opportunities, challenges, and best practices to address the rapidly changing landscape of artificial intelligence and machine learning in the setting of drug development and precision medicine.
This workshop will be open to the public with no cost to attend. To register please use this link. To view the agenda, please use this link. To view the speaker bios, please use this link.
About the Event
As compared to traditional statistical or pharmacometrics modeling, Artificial Intelligence (AI)/Machine Learning (ML) excels at handling high dimensional data and often has superior predictive capability, making it a powerful tool for prediction of clinical outcome, including disease prognosis and/or treatment response (for both efficacy and safety) based on patient characters as well as treatments information. AI/ML has potential to improve the efficiency of drug development and advance precision medicine, but also present challenges such as bias, issues with generalizability, opacity, disparity, fairness and trustworthiness.
- Review progress made from implementing artificial intelligence and machine learning in drug development and precision medicine.
- Discuss methodologies and best practices used today in this field
- Discuss technical challenges such as bias, generalizability, and opacity and how they can lead to issues of data disparity, fairness, and trustworthiness. We will also discuss how to address these challenges.
Meeting Information & Registration
The workshop which is jointly sponsored by the University of Maryland Center for Excellence in Regulatory Science and Innovation (M-CERSI) and the FDA, will be open to the public. Additional information is forthcoming.
This workshop is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award U01FD005946 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.